US2914528A - Substituted phenothiazinyl trifluoro-methyl sulfones - Google Patents
Substituted phenothiazinyl trifluoro-methyl sulfones Download PDFInfo
- Publication number
- US2914528A US2914528A US728773A US72877358A US2914528A US 2914528 A US2914528 A US 2914528A US 728773 A US728773 A US 728773A US 72877358 A US72877358 A US 72877358A US 2914528 A US2914528 A US 2914528A
- Authority
- US
- United States
- Prior art keywords
- trifluoromethylsulfonylphenothiazine
- acid
- hours
- solution
- extracted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 phenothiazinyl trifluoro-methyl sulfones Chemical class 0.000 title description 57
- 239000002253 acid Substances 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 23
- 239000012458 free base Substances 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 78
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 239000000725 suspension Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 238000010992 reflux Methods 0.000 description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 125000002947 alkylene group Chemical group 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000008096 xylene Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- YMPYIKFPIIYPQO-UHFFFAOYSA-N 2-(trifluoromethylsulfonyl)-10H-phenothiazine Chemical compound FC(S(=O)(=O)C1=CC=2NC3=CC=CC=C3SC2C=C1)(F)F YMPYIKFPIIYPQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 150000003457 sulfones Chemical class 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 4
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- AEXDMFVPDVVSQJ-UHFFFAOYSA-N trifluoro(trifluoromethylsulfonyl)methane Chemical class FC(F)(F)S(=O)(=O)C(F)(F)F AEXDMFVPDVVSQJ-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical compound C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- YAOMBFIYBNUKHD-UHFFFAOYSA-N thianthrene 5,5-dioxide Chemical class C1=CC=C2S(=O)(=O)C3=CC=CC=C3SC2=C1 YAOMBFIYBNUKHD-UHFFFAOYSA-N 0.000 description 3
- DEEBRJXOPCZLRT-UHFFFAOYSA-N 1-chloro-2-nitro-4-(trifluoromethylsulfanyl)benzene Chemical compound [O-][N+](=O)C1=CC(SC(F)(F)F)=CC=C1Cl DEEBRJXOPCZLRT-UHFFFAOYSA-N 0.000 description 2
- BDIMBZRJVHLTPD-UHFFFAOYSA-N 1-chloro-2-nitro-4-(trifluoromethylsulfonyl)benzene Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)C(F)(F)F)=CC=C1Cl BDIMBZRJVHLTPD-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FLNQAPQQAZVRDA-UHFFFAOYSA-N 1-(2-(2-Hydroxyethoxy)ethyl)piperazine Chemical compound OCCOCCN1CCNCC1 FLNQAPQQAZVRDA-UHFFFAOYSA-N 0.000 description 1
- KLJFMOLCQITNEG-UHFFFAOYSA-N 1-(3-bromopropyl)pyrrolidine Chemical compound BrCCCN1CCCC1 KLJFMOLCQITNEG-UHFFFAOYSA-N 0.000 description 1
- AUERUDPETOKUPT-UHFFFAOYSA-N 1-(3-chloropropyl)-4-methylpiperazine Chemical compound CN1CCN(CCCCl)CC1 AUERUDPETOKUPT-UHFFFAOYSA-N 0.000 description 1
- ZKDOQFPDSUOLGF-UHFFFAOYSA-N 1-bromo-3-chloro-2-methylpropane Chemical compound ClCC(C)CBr ZKDOQFPDSUOLGF-UHFFFAOYSA-N 0.000 description 1
- FAHOKEKRQVMPKI-UHFFFAOYSA-N 1-methylsulfonyl-10H-phenothiazine Chemical compound CS(=O)(=O)C1=C2NC3=CC=CC=C3SC2=CC=C1 FAHOKEKRQVMPKI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- HJNHUFQGDJLQRS-UHFFFAOYSA-N 2-(3-bromopropoxy)oxane Chemical compound BrCCCOC1CCCCO1 HJNHUFQGDJLQRS-UHFFFAOYSA-N 0.000 description 1
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-n,n-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NRCFEYDZHDVJKJ-UHFFFAOYSA-N 3-bromo-1-propylpiperidine Chemical compound CCCN1CCCC(Br)C1 NRCFEYDZHDVJKJ-UHFFFAOYSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QMSDUHFLDBPNEL-UHFFFAOYSA-N 4-(4,4-dihydroxybutoxy)butane-1,1-diol Chemical compound OC(O)CCCOCCCC(O)O QMSDUHFLDBPNEL-UHFFFAOYSA-N 0.000 description 1
- AAXQBYBEPAXJSE-UHFFFAOYSA-N 5-sulfonyl-10H-phenothiazine Chemical compound S(=O)(=O)=S1C=2C=CC=CC2NC2=CC=CC=C12 AAXQBYBEPAXJSE-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- IWTYTFSSTWXZFU-QPJJXVBHSA-N [(e)-3-chloroprop-1-enyl]benzene Chemical compound ClC\C=C\C1=CC=CC=C1 IWTYTFSSTWXZFU-QPJJXVBHSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002558 anti-leprotic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000005521 carbonamide group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- YTKRILODNOEEPX-NSCUHMNNSA-N crotyl chloride Chemical compound C\C=C\CCl YTKRILODNOEEPX-NSCUHMNNSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Definitions
- the compounds of this invention have utility asantiemetics, tranquilizers, calmatives, antihistamines, spasmolytics, antishock agents and potentiators of various central nervous system depressants, such as analgetics or anesthetics. Particularly important are the utilities of these compounds as antiemetics and tranquilizers.
- these compounds have chemotherapeutic or antimicrobial activity, such as antileprosy, antitubercular, antibacterial and fungicidal activity.
- they possess unusual fungicidal or antibacterial activity such as against Diplococcus pneumoniae Type I, Hemolytic streptococcus, Micrococcus pyogenes var. aureus, Klebsiella pneumoniae andCandida albicans.
- certain of these compounds have utility. as intermediates, aswill be evident from the following disclosure.
- the 10-substituted phenothiazinyl. trifluoromethyl sulfones, of this invention are represented by the general formula:
- R R R and R represent hydrogen, ethyl
- A represents a divalent, straight or branched alkylene chain containing 2 to 4 carbon atoms, advantageously propylene, separating the nitrogen atoms byat least 2. carbons;
- This invention also includes salts of the above defined bases formed with nontoxic organic and inorganic acids; Such salts are easily prepared by methods known to the art.
- the base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly.
- aqueous miscible solvent such as acetone or ethanol
- organic salts are those withv maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesal'icylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the S-halotheophyllines, for example, 8-chlorotheophy1line and 8-bromotheophylline.
- the SO CF group is preferably in the 2-position.
- X represents chloro, bromo or iodo.
- the method is carried out by heating the sulfonyldiphenyl sulfides of Formula 5 in the presence of an acid-binding agent present in at least an amount sufficient to neutralize the hydrohalic acid formed during the reaction.
- acid-binding agents are the carbonates, such as sodium carbonate, sodium bicarbonate or preferably potassium carbonate.
- the reaction is run in a suitable, non-reactive organic solvent in which the reactants are at least partially soluble.
- exemplary are dioxane, dimethylaniline, diethylformamide, methylformarnide, dimethylforinamide or dimethylacetamide.
- the solvent is dimethylformamide and other similar lower carbon amides.
- sulfonyldiphenyl sulfidese are prepared by method analogous to those in the prior art, for instance as illustrated hereafter for the preparation of Z-trifluoromethylsulfonylphenothiazine: 1
- 3-nitro-4-chlorophenyl trifluoromethyl sulfide is oxidized to the corresponding sulfone with chromic anhydride in sulfuric acid.
- the 3-nitro-4-chlorophenyl trifiuoromethyl sulfone is condensed with obromothiophenol under alkaline conditions to give the diphenyl sulfide.
- the 2-nitro group is reduced with stannous chloride-hydrochloric acid to give 2-bromo-2-amino-4-trifluoromethylsulfonyldiphenyl sulfide which is then further reacted as described above.
- the selected phenothiazinyl trifluoromethyl sulfones of Formula 4 are condensed with a reactive tertiary aminoalkyl ester having the desired dialkylaminoalkyl group to form the desired IO-aminoalkylphenothiazinyl trifluoro-.
- aminoalkyl ester containing the Any reactive tertiary desired moiety may be used, such as the halides, preferably bromide or chloride, or the sulfonic esters, preferably p-toluene sulfonate.
- the reaction is preferably carried out at a temperature in the range of from about 30 C. to about C.
- the condensation is carried out advantageously by refluxing the reactants in an inert aromatic solvent such as, preferably, benzene, toluene or xylene, in which at least one of the reactants must be soluble.
- a suitable acid-binding agent is usually included, such as an alkali metal amide, preferably, sodium, potassium or lithium amide.
- acid-binding agents are alkali metal hydride, preferably sodium hydride or alkali metal aryl or alkyl compounds, preferably phenyl or actyl sodium. If the acid addition salt of the reactive ester is used, a corresponding increase in acid-binding agent must be used.
- the w.-piperazinylalkylphenothiazinyl trifluoromethyl. sulfones are prepared advantageously by alkylating a trifluoromethylsulfonylphenothiazine (Formula 4) with an w-haloalkylpiperazine with the free N-hydrogen of the piperazinyl moiety protected by, for example, a benzyl, carbobenzoxy, or acyl, preferably formyl group. The N- protective group is then removed, such as by mild hydrolysis. The resulting w-piperazinyl alkylphenothiazinylsulfone may then be further alkylated to form various modifications of the compounds of.
- Such methods of alkylation are by a reactive ester such as an alkyl halide in the presence of an acid-binding agent in inert solution such as benzene or butanone, by reaction with an alkylene oxide such as ethylene oxide in alcohol or by reduction of a N-acyl compound such as reduction of the N-acyl analogue with a bimetallic hydride such as lithium aluminum hydride.
- Another route to these compounds is by means of w-ester alkylphenothiazinyl trifluoromethyl sulfones which have a reactive end group on the lO-alkyl chain, for example, an w-tosylate or w-chloro end group, which can be reacted with various amines to form primary or secondary amines, for instance by refluxing the ester and amine in the presence of an acid binder for short periods.
- w-ester alkylphenothiazinyl trifluoromethyl sulfones which have a reactive end group on the lO-alkyl chain, for example, an w-tosylate or w-chloro end group, which can be reacted with various amines to form primary or secondary amines, for instance by refluxing the ester and amine in the presence of an acid binder for short periods.
- the isomers may be'separated for individual use by separation methods known to the art, such as fractional crystallization, for instance, of the d-tartrate salts of the lO-aminoalkylated trifluoromethylsulfonylphenothiazine derivatives.
- separation methods known to the art, such as fractional crystallization, for instance, of the d-tartrate salts of the lO-aminoalkylated trifluoromethylsulfonylphenothiazine derivatives.
- a synthesis starting with an optically active side chain may yield the desired opticalisomer.
- Example 1 A solution of 8.0 g. of chromic anhydride, 8.0 g. of sulfuric acid and 25 ml. of water is mixed with 15.4 g. of
- Example 4 A mixture of 16.5 g. of Z-trifluoromethylsulfonyh phenothiazine (made as in Example 1), 2.4 g. of sodamide and 10.5 g. of 1-(3-chloropropyl)-4-methylpiperazine in 200 ml. of xylene is stirred and refluxed for four hours. The reaction mixture is extracted with water and the separated xylene layer extracted portion-wise with dilute hydrochloric acid. The combined acid extracts are The mixture is stirred and re- 7 neutralized with ammonium hydroxide and the product taken up in benzene.
- the solvent is distilled ofl in vacuo, leaving the residual -[3'-(N-formylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine as a viscous oil.
- Example 6 A stirred suspension of 22.8 g. of 10-(3'-piperazinylpropyl) -2-trifluoromethylsulfonylphenothiazine (prepared as in Example 6), 8.9 g. of B-bromoethyl acetate and 3.6 g. of potassium carbonate in 200 m1. of toluene is refluxed for 16 hours; The cooled reaction mixture is treated with water and the separated organic layer extracted with dilute acid. The combined acid extract is neutralized, further extracted with benzene and upon evaporation of the solvent in vacuo, an oily residue is obtained which is purified by chromatography through alumina.
- Example 8 A solution of 2.2 g. of l0-[3'-(N-acetoxyethylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine (prepared as in Example 7) in 50 ml. of l N hydrochloric acid is refluxed for a short time. The reaction mixture is neutralized with dilute sodium carbonate solution and extracted with benzene. Evaporation of the solvent gives 10-[3(N-B-hydroxyethylpiperazinyl)-propyl]-2-trifiuoromethylsulfonylphenothiazine as an oil.
- Example 9 azinyl) -propyl]-2-trifluoromethylsulfonylphenothiazine.
- Example 10 To a solution of 4.6 g. of l0-(3'-piperazinylpropyl)-2- trifiuoromethylsulfonylphenothiazine (made as in Example 6) in 150.0 g. of benzene, 1.8 g. of phenylacetyl chloride is added dropwise with swirling. The mixture, after standing overnight, is filtered to give crystals of 10-[3' (N phenylacetylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine hydrochloride.
- Example 11 A suspension of 9.2 g. of 10-(3-piperazinylpropyl)-2- trifluoromethylsulfonylphenothiazine, 5.6 g. of 4-bromo- 4'-hydroxybutyl ether (prepared by carefully treating 4,4-dihydroxybutyl ether with one equivalent of hydrobromic acid) and 4.2 g. of potassium carbonate in 200 ml. of xylene is heated at reflux for 24 hours. After treating the reaction mixture with water, the separated organic layer is extracted with acid. The acidic extracts are made basic and extracted with benzene. Removal of the solvent from the dried extracts yields l0-[3-(N-hydroxybutoxybutylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine.
- Example 13 A mixture of 9.2 g. of l0-(3-piperazinylpropyl)-2-trifiuoromethylsulfonylphenothiazine, 1.8 g. of crotyl chloride and 1.6 g. of potassium carbonate in ml. of aqueous ethanol is stirred and heated at reflux for six hours. The reaction mixture is worked up as outlined in Example 7 to give lO-[3-(N-crotylpiperazinyl)-propyl]2-trifiuoromethylsulfonylphenothiazine.
- a solution of the free base (1.0 g.) in ethyl acetate is treated with a solution of mandelic acid in ethanol. Concentration and cooling of the resulting solution yields the dimandelate salt.
- Example 23 A suspension of 9.1 g. of 10 (3-piperazinylpropyl)-2- tr'ifiuoromethylsulfonylphenothiazine (made as in Example 6), 0.8 g. of sodium amide and 3.3 g. of 2-bromo-ldimethylaminoethane in ml. of benzene is refluxed for six hours, With stirring. Treating the reaction mixture as in Example 20 gives the product, 10-[3-(N- 3-dimethylaminoethylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine.
- Example 24 A stirred suspension of 9.1 g. of l0-(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine *(made as in Example 6), 3.4 g. of w-bromobutanol and 4.0 g. of potassium carbonate in 125 ml. of xylene is refluxed for six hours. Water is added to the reaction mixture and the separated xylene layer is extracted with dilute hydrochloric acid. The acid extracts are neutralized and extracted with benzene. The solvent is distilled in vacuo to give a residue of 10-[3'-(N-w-hydroxybutylpiperazinyl)- propyl] -2'-trifluoromethylsulfonylphenothiazine.
- Example 25 A mixture of 10.8 g. of 10-(3'-hydroxypropyl)-2-trifiuoromethylsulfonylphenothiazine p toluenesulfonate (prepared as outlined in Example 18), 5.0 g. of N- hydroxyethoxyethylpiperazine and 4.2 g. of potassium carbonate in 150 ml. of ethanol is heated at reflux for six hours, with stirring. The reaction mixture is treated with water, evaporated in vacuo and extracted with ethyl acetate. Evaporation of the dried solvent yields the product, 10 [3' (N hydroxyethoxyethylpiperazinyl) propyl] 2-trifluoromethylsulfonylphenothiazine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
SUBSTITUTED PHENOTHIAZINYL TRIFLUORO- METHYL SULFONES Paul N. Craig, Roslyn, Pa., assignor to Smith, Kline & French Laboratories, Philadelphia, Pa., a corporation of Pennsylvania N Drawing. Application April "16, 1958 Serial No. 728,773
10 Claims. (Cl. 260-243) This invention relates to new IO-aminoalkylphenothiazinyl trifluoromethyl sulfones of value as therapeutic agents. Further, this invention relates to novel phenothiazinyl trifiuoromethyl sulfone intermediates.
More specifically, the compounds of this invention have utility asantiemetics, tranquilizers, calmatives, antihistamines, spasmolytics, antishock agents and potentiators of various central nervous system depressants, such as analgetics or anesthetics. Particularly important are the utilities of these compounds as antiemetics and tranquilizers. In addition, these compounds have chemotherapeutic or antimicrobial activity, such as antileprosy, antitubercular, antibacterial and fungicidal activity. For example, they possess unusual fungicidal or antibacterial activity, such as against Diplococcus pneumoniae Type I, Hemolytic streptococcus, Micrococcus pyogenes var. aureus, Klebsiella pneumoniae andCandida albicans. Further, certain of these compounds have utility. as intermediates, aswill be evident from the following disclosure.
The 10-substituted phenothiazinyl. trifluoromethyl sulfones, of this invention are represented by the general formula:
FORMULA 1 2 when FORMULA 2 N NR7 5 6 when:
R R R and R represent hydrogen, ethyl; and
R represents hydrogen, alkyl, acyloxyalkylene such as alkanoyloxyalkylene or monocyclic aroyloxy-alkylene such as benzoyloxyalkylene, hydroxyalkylene, dialkylmethyl or ice 2- aminoalkylene, hydroxy alkyleneoxyalkylene, monocya clic aralkyl of from 7 tell) carbons such as cinnamyl and phenylalkyl, or acyl, such as alkanoyl, phenyl alkanoyl, monocyclic aroyl, carbobenzoxy or lower N-substituted carbamyl such as dialkyl carbamyl.
The preferred substituted piperazinyl moieties are N-hydrogen piperazinyl, N-alkylpiperazinyl, N-(w-hydroxyalkylene) piperazinyl, N- w-alkanoyloxyalkylene) piperazinyl, N-(w-monocyclic aroyloxy-alkylene)-piperazinyl, N-monocyclic aralkylpiperazinyl, N-alkanoylpiperazinyl, N,2,3,5,6-pentamethylpiperazinyl or N-(whydroxy-alkyleneoxy-alkylene) piperazinyl.
The SO CF group is preferably in the 2' position. The preferred compounds of this invention are represented by the following structural formula:
When:
A represents a divalent, straight or branched alkylene chain containing 2 to 4 carbon atoms, advantageously propylene, separating the nitrogen atoms byat least 2. carbons; and
Z represents dimethylamino, piperazinyl or N-substituted piperazinyl, specifically alkyl, alkanoyloxyalkylene, hydroxy-alkyleneoxy-alkylene or hydroxy alkylene piperazinyl. I
By the term alkyl or alkanoyl where used herein alone or in combination with other terms, aliphatic groups having not more than 6carbon atoms and preferably not more than 4 carbon atoms are indicated except where otherwise specified. When the term alkylene is used in connection with a carbon chain, this term rep resents aliphatic groups of from 2 to 6 carbon atoms, preferably 2 to 4 carbons except where otherwise speci fied.
This invention also includes salts of the above defined bases formed with nontoxic organic and inorganic acids; Such salts are easily prepared by methods known to the art. The base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly. Exemplary of such organic salts are those withv maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesal'icylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the S-halotheophyllines, for example, 8-chlorotheophy1line and 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course these salts may also be prepared by' the classical method of double decomposition of appropriate salts which is well-known to the art.
The novel phenothiazinyl trifluoromethyl sulfones, which are unsubstituted in the lO-position, are used as intermediates to prepare the biologically active IO-aminoalkylphenothiazinyl trifluoromethyl sulfones described in Formula 1; While these unsubstituted phenothiazinyl trifluoromethyl sulfones have utility particularly as intermediates, as indicated, they have significant 'antifungal FORMULA 4 sole F,
The SO CF group is preferably in the 2-position.
The compounds of Formula 4 are prepared by cyclizing the sulfonyldiphenylsulfides represented by the following formula:
FORMULA 5 XNH; 3
when:
R; and R are different and selected from the group consisting of H and -SO CF preferably in the 4 or 4' positions; and
X represents chloro, bromo or iodo.
Preferably R is hydrogen, R is SO CF in the 4- position, and X is bromo or iodo.
The method is carried out by heating the sulfonyldiphenyl sulfides of Formula 5 in the presence of an acid-binding agent present in at least an amount sufficient to neutralize the hydrohalic acid formed during the reaction. Exemplary of such acid-binding agents are the carbonates, such as sodium carbonate, sodium bicarbonate or preferably potassium carbonate. The reaction is run in a suitable, non-reactive organic solvent in which the reactants are at least partially soluble. Exemplary are dioxane, dimethylaniline, diethylformamide, methylformarnide, dimethylforinamide or dimethylacetamide. Preferably, the solvent is dimethylformamide and other similar lower carbon amides.
Optimum yields are obtained when catalytic amounts of copper or copper bronze powder are added, for instance up to 5% by weight of the diphenyl sulfide. The reaction mixture is advantageously heated at from about 100 to 220 C. for long periods, such as from 4 to 60 hours. Preferably, the reaction mixture is heated with stirring at the boiling point of the solvent for from about 8 to 24 hours. The reaction mixture is worked up by cooling, filtering and quenching in water. The separated product is washed, recrystallized and optionally sublimed to give the desired sulfonylphenothiazine, usually as yellow crystals.
This reaction may be advantageously run in an alternative manner, namely, by alkylating the 2-amino-2'- halo-X-sulfonyldiphenyl sulfide prior to the cyclization thereby substituting the primary amine with a tertiary alkylaminoalkyl moiety which is not reactive under the cyclization conditions subsequently employed. This alltylation is carried out under conditions identical with those described hereafter for the lO-alkylation of the phenothiazinyl trifluoromethyl sulfones. The cyclization conditions of the alkylated amine are identical to those described above. a
The sulfonyldiphenyl sulfidese are prepared by method analogous to those in the prior art, for instance as illustrated hereafter for the preparation of Z-trifluoromethylsulfonylphenothiazine: 1
4 METHOD A son, so,o r,
I --v NO; NO: SE
S030 F; N H
SOQGF N t l --N In Method A, 3-nitro-4-chlorophenyl trifluoromethyl sulfide is oxidized to the corresponding sulfone with chromic anhydride in sulfuric acid. The 3-nitro-4-chlorophenyl trifiuoromethyl sulfone is condensed with obromothiophenol under alkaline conditions to give the diphenyl sulfide. The 2-nitro group is reduced with stannous chloride-hydrochloric acid to give 2-bromo-2-amino-4-trifluoromethylsulfonyldiphenyl sulfide which is then further reacted as described above.
The selected phenothiazinyl trifluoromethyl sulfones of Formula 4 are condensed with a reactive tertiary aminoalkyl ester having the desired dialkylaminoalkyl group to form the desired IO-aminoalkylphenothiazinyl trifluoro-.
methyl sulfone of Formula 1. aminoalkyl ester containing the Any reactive tertiary desired moiety may be used, such as the halides, preferably bromide or chloride, or the sulfonic esters, preferably p-toluene sulfonate. The reaction is preferably carried out at a temperature in the range of from about 30 C. to about C. The condensation is carried out advantageously by refluxing the reactants in an inert aromatic solvent such as, preferably, benzene, toluene or xylene, in which at least one of the reactants must be soluble. A suitable acid-binding agent is usually included, such as an alkali metal amide, preferably, sodium, potassium or lithium amide. Other acid-binding agents are alkali metal hydride, preferably sodium hydride or alkali metal aryl or alkyl compounds, preferably phenyl or actyl sodium. If the acid addition salt of the reactive ester is used, a corresponding increase in acid-binding agent must be used.
The preferred method of alkylation, however, is to react the trifluoromethylsulfonylphenothiazine nucleus with a dialkylarninoalkyl chloride or bromide with a slight excess of sodium or potassium amide in refluxing benzene or toluene for from 30 minutes to 36 hours, preferably 3 to 8 hours.
The preferred method of isolating the IO-aminoalkylphenothiazinyl tr fluommst yl sulfone is to quench the cooled reaction mixtures with an excess of water. The organic layers are extracted with dilute acid, preferably dilute hydrochloric acid. The acid extracts are combined, neutralized and extracted with benzene. The dried benzene extracts are evaporated to give the desired compound, usually as a solid.
The w.-piperazinylalkylphenothiazinyl trifluoromethyl. sulfones are prepared advantageously by alkylating a trifluoromethylsulfonylphenothiazine (Formula 4) with an w-haloalkylpiperazine with the free N-hydrogen of the piperazinyl moiety protected by, for example, a benzyl, carbobenzoxy, or acyl, preferably formyl group. The N- protective group is then removed, such as by mild hydrolysis. The resulting w-piperazinyl alkylphenothiazinylsulfone may then be further alkylated to form various modifications of the compounds of. Formula 1 with optional variations of the moieties of Formula 2. Such methods of alkylation are by a reactive ester such as an alkyl halide in the presence of an acid-binding agent in inert solution such as benzene or butanone, by reaction with an alkylene oxide such as ethylene oxide in alcohol or by reduction of a N-acyl compound such as reduction of the N-acyl analogue with a bimetallic hydride such as lithium aluminum hydride.
Another route to these compounds is by means of w-ester alkylphenothiazinyl trifluoromethyl sulfones which have a reactive end group on the lO-alkyl chain, for example, an w-tosylate or w-chloro end group, which can be reacted with various amines to form primary or secondary amines, for instance by refluxing the ester and amine in the presence of an acid binder for short periods.
The primary IO-(aminoalkyl)-phenothiazinyl trifluoromethyl sulfones are alternatively produced by reacting a trifluoromethylsulfonylphenothiazine of Formula 4 with an excess of acrylonitrile or in an inert solvent such as benzene in the presence of a catalytic amount of strong base, such as a quaternary base, for instance benzyltrimethylammonium hydroxide. The resulting fi-cyanoethyl compound is then reduced, for instance, with lithium aluminum hydride to give the primary amine. Further alkylation of the primary amine gives other compounds of this invention.
The foregoing is a general description of the main synthetic routes in the preparation of lO-(w-aminoalkyD-X- trifluoromethylsulfonylphenothiazine derivatives. It will be readily apparent to one skilled in the art that variations of these procedures arepossible. Of particular advantage as preparative procedures are the methods thoroughly discussed above, especially, N-alkylation of 2-trifluoromethylsulfonylphenothiazine in the -position of the nucleus by a reactive dialkylaminoalkyl ester.
It will be readily apparent to one skilled in the art that certain of the compounds of this invention, notably those in which A is represented by an aliphatic carbon chain branched so that an asymmetric carbon atom is formed or where R and R are alkyl, may be present as optical or cistrans isomers. The connotation of the general formulae presented herein is to include all isomers, particularly the separated d or [optical isomers as well as the dl mixture of these isomers. If desired, the isomers may be'separated for individual use by separation methods known to the art, such as fractional crystallization, for instance, of the d-tartrate salts of the lO-aminoalkylated trifluoromethylsulfonylphenothiazine derivatives. Alternatively, a synthesis starting with an optically active side chain may yield the desired opticalisomer.
The following examples are not limiting but are illustrative of compounds of this invention and the procedures for their preparation and will serve to make fully apparent all of the compounds embraced by the general formula given above and the preparation thereof respectively.
Example 1 A solution of 8.0 g. of chromic anhydride, 8.0 g. of sulfuric acid and 25 ml. of water is mixed with 15.4 g. of
3-nitro-4-chlorophenyl trifluoromethyl sulfide and? the resulting mixture is stirred for 15 hours at -130? C. Steam distilling the reaction mixture yields 3-nitro-4- chlorophenyl trifluoromethyl sulfone.
A solution of 4.0 g. of sodium hydroxide pellets in 30 ml. of water is added to 18.9 g. of Z-bromothiophenol dissolved in 250 ml. of ethanol and the resulting mixture added to a solution of 28.9 g. of 3-nitro-4-chlorophenyl trifluoromethyl sulfone in 100 ml. of ethanol. The suspension is refluxed for three hours. The solid present is filtered from the hot reaction mixture and washed several times with hot ethanol. The combined alcoholic filtrate is diluted with a'small amount'of water and cooled to yield 2-bromo-2-nitro-4-trifluoromethylsulfonyldi phenyl sulfide. i
A solution of 225.7 g. of'stannous chloride crystals in 750 ml. of concentrated hydrochloric acid is carefully mixed with 44.2 g. of2'-bromo-2-nitro-4-trifiuoromethyl sulfonyldiphenyl sulfide. fluxed for five hours. The cooled reaction mixture is filtered and the separated solid metal complex is broken up by hydrolysis for one hour atrefiux with 10% caustic soda and washed with benzene. The organic layer is separated and combined with further benzene washes. The solvent. is then removed by distillation in vacuo and upon purification of the residue, 2'-bromo-2-'amino-4-trifiuoromethylsulfonyldiphenyl sulfide is obtained.
A suspension of 20.6 g. of 2'-bromo-2-amino-4-trifluoromethylsulfonyldiphenyl sulfide, 8.3 g. of anhydrous potassium carbonate and 0.4 g. of copper-bronze powder in 200 ml. of dimethylformamide is stirred and heated at reflux for 18 hours. The cooled reaction mixture is filtered and the filtrate diluted with water. The solid which thus forms is vacuum sublimed at 0.05 mm. (-195 C.) and recrystallized to give pure Z-trifluoromethylsulfonylphenothiazine.
Example 2 A suspension of 33.1 g. of Z-trifluoromethylsulfonylphenothiazine (prepared as in Example 1) and 2.4 g. of lithium amide in 100 ml. of dry toluene is stirred vigorously, slowly heated ot reflux temperature and refluxed for two hours. A solution of 13.3 g. of 3-chloro-l-dimethylaminopropane in 10 ml. of toluene is then added slowly and the resulting mixture refluxed for four hours. After decomposing the excess lithium amide by the cantious addition of 10 ml. of water, the toluene layer is separated and water washed. The dried solvent is removed in vacuo and the residue chromatographed through alumina to give 10-(3'-dimethylaminopropyl) -2-trifluoromethylsulfonylphenothiazine.
A solution of 1.0 g. of the base in 25 ml. of dry ether is treated with ethereal hydrogen chloride yielding the hydrochloride salt.
Example 3 A suspension of 6.6 g. of Z-trifluoromethylsulfonylphenothiazine (made as in Example 1), 1.2 g. of potassium amide and 2.7 g. of Z-chloro-l-dimethylaminopropane in 100 ml. of toluene is heated at reflux for four hours. The reaction mixture is water-washed, extracted With dilute mineral acid and acidic extracts neutralized with aqueous ammonia. Upon benzene extraction, the residual basic oil is reacted with bismethylenesalicyclic acid in ethyl acetate solution. to give, after purification, 10 (dimethylaminoisopropyl) 2 trifluoromethylsulfonylphenothiazine bismethylenesalicylate.
Example 4 A mixture of 16.5 g. of Z-trifluoromethylsulfonyh phenothiazine (made as in Example 1), 2.4 g. of sodamide and 10.5 g. of 1-(3-chloropropyl)-4-methylpiperazine in 200 ml. of xylene is stirred and refluxed for four hours. The reaction mixture is extracted with water and the separated xylene layer extracted portion-wise with dilute hydrochloric acid. The combined acid extracts are The mixture is stirred and re- 7 neutralized with ammonium hydroxide and the product taken up in benzene. Removal of the solvent and chromatography over alumina yields 10-[3'-(4-methy1-1"- piperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine. Treating the oil with maleic acid in ethyl acetate results in theformation of the dimaleate salt.
Example 5 A suspension of 66.2 g. of Z-trifluoromethylsulfonylphenothiazine (made as in Example 1) and 8.2 g. of sodium amide in 900 m1. of toluene is heated at reflux with rapid stirring for 15 minutes. A solution of 41.8 g. of l-formyl-4-(3'-chloropropyl)-piperazine in 100 ml. of toluene is added and refluxing continued for six hours. The cooled reaction mixture is treated with 150 ml. of water and toluene layer extracted with dilute hydrochloric acid. The acid extracts are made basic with ammonia and extracted with benzene. The solvent is distilled ofl in vacuo, leaving the residual -[3'-(N-formylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine as a viscous oil.
Example 6 Example 7 A stirred suspension of 22.8 g. of 10-(3'-piperazinylpropyl) -2-trifluoromethylsulfonylphenothiazine (prepared as in Example 6), 8.9 g. of B-bromoethyl acetate and 3.6 g. of potassium carbonate in 200 m1. of toluene is refluxed for 16 hours; The cooled reaction mixture is treated with water and the separated organic layer extracted with dilute acid. The combined acid extract is neutralized, further extracted with benzene and upon evaporation of the solvent in vacuo, an oily residue is obtained which is purified by chromatography through alumina. A solution of the free base in ether is treated with ethereal hydrogen chloride to give l0-[3(N-acetoxyethylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine dihydrochloride.
Example 8 A solution of 2.2 g. of l0-[3'-(N-acetoxyethylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine (prepared as in Example 7) in 50 ml. of l N hydrochloric acid is refluxed for a short time. The reaction mixture is neutralized with dilute sodium carbonate solution and extracted with benzene. Evaporation of the solvent gives 10-[3(N-B-hydroxyethylpiperazinyl)-propyl]-2-trifiuoromethylsulfonylphenothiazine as an oil.
Example 9 azinyl) -propyl]-2-trifluoromethylsulfonylphenothiazine.
for four hours.
Example 10 To a solution of 4.6 g. of l0-(3'-piperazinylpropyl)-2- trifiuoromethylsulfonylphenothiazine (made as in Example 6) in 150.0 g. of benzene, 1.8 g. of phenylacetyl chloride is added dropwise with swirling. The mixture, after standing overnight, is filtered to give crystals of 10-[3' (N phenylacetylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine hydrochloride.
Example 11 A suspension of 9.2 g. of 10-(3-piperazinylpropyl)-2- trifluoromethylsulfonylphenothiazine, 5.6 g. of 4-bromo- 4'-hydroxybutyl ether (prepared by carefully treating 4,4-dihydroxybutyl ether with one equivalent of hydrobromic acid) and 4.2 g. of potassium carbonate in 200 ml. of xylene is heated at reflux for 24 hours. After treating the reaction mixture with water, the separated organic layer is extracted with acid. The acidic extracts are made basic and extracted with benzene. Removal of the solvent from the dried extracts yields l0-[3-(N-hydroxybutoxybutylpiperazinyl) propyl] 2 trifluoromethylsulfonylphenothiazine.
Example 12 A stirred suspension of 16.5 g. of 2-trifluoromethylsulfonylphenothiazine and 3.9 g. of sodamide in 150 ml. of xylene is refluxed while 13.6 g. of 3-bromo-1-pyrrolidinylpropane hydrobrornide is added portion-wise. After the addition is complete, stirring and heating is continued for 15 hours. The cooled reaction mixture is carefully treated with ice water. The separated organic layer combined with several benzene washes is extracted with dilute hydrochloric acid. The acid extracts are neutralized with sodium hydroxide solution and then ether extracted. Evaporation of the ether gives l0-(3'-N-pyrrolidinylpropyl) -2-trifluoromethylsulfonylphenothiazine.
A solution of the base in ether is treated with glacial acetic acid to give the acetate salt.
Example 13 A mixture of 9.2 g. of l0-(3-piperazinylpropyl)-2-trifiuoromethylsulfonylphenothiazine, 1.8 g. of crotyl chloride and 1.6 g. of potassium carbonate in ml. of aqueous ethanol is stirred and heated at reflux for six hours. The reaction mixture is worked up as outlined in Example 7 to give lO-[3-(N-crotylpiperazinyl)-propyl]2-trifiuoromethylsulfonylphenothiazine.
Similarly, using cinnamyl chloride as described above, 10 [3 (N cinnamylpiperazin-yl) propyl] 2 trifiuoromethylsulfonylphenothiazine is obtained.
Example 14 A suspension of 33.1 g. of Z-trifluoromethylsulfonylphenothiazine (prepared as in Example 1) and 2.4 g. of lithium amide in 100 ml. of dry toluene is refluxed for two hours. A solution of 14.9 g. of 2-chloro-l-diethylaminoethane in 25 ml. of toulene is added slowly and the resulting mixture refluxed for four hours. The excess lithium amide is decomposed by the addition of 20 ml. of water. The toluene layer is separated and washed with water. The dried solvent is removed in vacuo to yield crude l0-(2-diethylaminoethyl)-2-trifiuoromethylsulfonylphenothiazine.
A solution of 1.0 g. of the base in 25 ml. of dry other is treated with excess ethereal hydrogen chloride to give the hydrochloride salt.
Example 15 A suspension of 16.5 g. of Z-trifiuoromethylsulfonylphenothiazine (prepared as in Example 1), 16.2 g. of N carbobenzoxy N (a chloro 3 methylpropyl)- piperazine (prepared from the reaction of N-ca-rbobenzoxypiperazine with 3-bromo-2-methylpropyl chloride) and 2.2 g. of sodamide in 250 m1. of toluene is refluxed The reaction mixture is treated with 9 Water and the organic layer is separated and washed with water. The dried solvent is removed in vacuo to yield 10 [3 (N carbobenzoxypiperazinyl) 2' methylpropyl] -2-trifluorom ethylsulfonylphenothiazine.
A solution of 18.0 g. of 10-[3-(N-carbobenzoxypiperazinyl) 2 methylpropyl] 2 trifluoromethylsulfonylphenothiazine in 200 ml. of aqueous ethanol and 10 ml. of 40% sodium hydroxide solution is refluxed for four hours. After removal of the alcohol in vacuo, the residue is treated with benzene and Water. The dried benzene layer is evaporated to give the product 10-(2'-methy1-3'- piperazinylpropyl) 2 trifluoromethylsulfonylphenothiazme.
A solution of the free base (1.0 g.) in ethyl acetate is treated with a solution of mandelic acid in ethanol. Concentration and cooling of the resulting solution yields the dimandelate salt.
Example 16 A mixture of 14.1 g. of 10-(2'-methyl-3'-piperazinylpropyl) -2-trifluoromethylsulfonylphenothiazine' (prepared as in Example and 60 ml. of 85% formic acid solution is warmed to 50 C., after which ml. of 37% formalin solution is added slowly. The temperature of the reaction mixture is maintained at 50 to 60 C. until there is no further evolution of carbon monoxide. The mixture is neutralized with dilute sodium hydroxide solution and extracted With benzene. Removal of the dried solvent and vacuum distillation of the residue gives 10- [3' (4" methyl 1 piperazinyl) 2' methylpropyll- 2-trifluoromethylsulfonylphenothiazine.
A solution of 1.0 g. of the free base in ml. of dry ether is treated with an excess of ethereal hydrogen chloride to give the dihydrochloride salt.
Example 17 To a stirred suspension of 19.2 g. of 10-(2-cyanoethyl)-2-trifiuoromethylsulfonylphenothiazine (prepared from the reaction of 2-trifluoromethylsulfonylphenothiazine, which is prepared as in Example 1', and acrylonitrile with benzyltrimethylammonium hydroxide) in 700 ml. of dry ether, a solution of 8.0 g. of lithium aluminum hydride in 250 m1. of ether is added slowly. The mixture is refluxed for eight hours, cooled and treated with methanol to destroy the metal complex. After filtration, the filtrate is evaporated and the residue extracted several times with dilute hydrochloric acid. The acidic extracts are neutralized and extracted with chloroform. Evaporation of the solvent yields 10-(3'-aminopropyl)- 2-trifluoromethylsulfonylphenothiazine.
Example 18 A mixture of 16.3 g. of 10-(3'-hydroxypropyl)-2-trifluoromethylsulfonylphenothiazine p-toluene sulfonate (prepared by condensing the sodio derivative of 2-trifluoromethylsulfonylphenothiazine with bromopropyltetrahydropyranyl ether, hydrolyzing the protective pyranyl group with hydrochloric acid and acylating the resulting 'y-hydroxy compound with excess p-toluenesulfonyl chloride in pyridine) and 9.0 g. of butylamine in 75 ml. of ethanol is refluxed for ten hours. The reaction mixture is evaporated on the steam bathand the residue extracted with a water-chloroform mixture. The organic layer is separated and extracted with dilute hydrochloric acid. The acid extracts are neutralized with sodium carbonate solution and extracted with ethyl acetate. Treating the ethyl acetate solution with maleic acid results in the formation of 10-(3'-butylaminopropyl)- Z-tn'fiuoromethylsulfonylphenothiazine maleate.
Example 19 A suspension of 33.1 g. of 2-trifluoromethylsulfonylphenothiazine (prepared as in Example 1) and 2.4 g. of lithium amide in 125 ml. of xylene is mixed slowly with a solution of 22.7 g. of 3-bromo-1-piperidylpropane in ml. of' xylene at 100 C. The mixture is then refluxed for four hours, cooled and treated with water. The organic layer is extracted with acid and the acid extracts are neutralized with ammonium hydroxide solution. The resulting solution is extracted with benzene; the solvent is then removed by distillation in vacuo to give the product, 10-(3'-N-piperidylpropyl)-2-trifluoromethylsulfonylphenothiazine.
Example 20 A suspension of 6.6 g. of Z-trifluoromethylsulfonylphenothiazine (prepared as in Example 1), 0.8 g. of sodamide and 5.1 g. of 3-chloro-1-(1,2',3',5',6'-pentamethylpiperazinyD-propane-in 150 ml. of toluene is refluxed for four hours. The reaction mixture is treated with water and the organic layer extracted several times with dilute hydrochloric acid. The acid extracts are neutralized with ammonium hydroxide solution and extracted with benzene. The solvent. is removed yielding the product, 10- [3' (1",2,3",5,6" pentamethylpiperazinyl) pro pyl] -2-trifluoromethylsulfonylph eno thiazine.
By treating 1.0 g. of the. free base with excess maleic acid in ethyl acetate solution, the dimaleate'salt is obtained.
Example 21 A mixture of 6.6 g. of 2-trifluoromethylsulfonylphenothiazine (made as in Example 1), 0.8 g. of sodamide and 5.1 g. of 3-chloro-1-(1'-methyl-2,5-diethylpiperazinyl)- propane in 250 ml. of toluene is refluxed for four hours. Working up the mixture as described in Example 20 yields the product, 10-[3- l"-methyl-2",5"-diethylpiperazinyl)- propyl] -2-trifluoromethylsulfonylphenothiazine.
Example 22 A mixture of 19.4 g. of 10-(3'-aminopropyl)-2-trifluoro methylsulfonylphenothiazine (made as in Example 17) and 10.9 g. of butyl bis-(,B-chloroethyD-amine in 150 ml. of butanol is refluxed for nine hours. T ributylarnine (20 ml.) is added and the refluxing continued for eight hours. The reaction mixture is concentrated by heating on the steam bath under reduced pressure, diluted with water and extracted with chloroform. The extracts are evaporated to yield the residue, 10-[3'-(4-butyl-1"-piperazinyl)-propyl] -2-trifluoromethylsulfonylphenothiazine.
A solution of the free base (1.0 g.) in 50 ml. of acetone is reacted with an excess of citric acid in acetone to give the dicitrate salt.
Example 23 A suspension of 9.1 g. of 10 (3-piperazinylpropyl)-2- tr'ifiuoromethylsulfonylphenothiazine (made as in Example 6), 0.8 g. of sodium amide and 3.3 g. of 2-bromo-ldimethylaminoethane in ml. of benzene is refluxed for six hours, With stirring. Treating the reaction mixture as in Example 20 gives the product, 10-[3-(N- 3-dimethylaminoethylpiperazinyl) propyl] 2 trifiuoromethylsulfonylphenothiazine.
Example 24 A stirred suspension of 9.1 g. of l0-(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine *(made as in Example 6), 3.4 g. of w-bromobutanol and 4.0 g. of potassium carbonate in 125 ml. of xylene is refluxed for six hours. Water is added to the reaction mixture and the separated xylene layer is extracted with dilute hydrochloric acid. The acid extracts are neutralized and extracted with benzene. The solvent is distilled in vacuo to give a residue of 10-[3'-(N-w-hydroxybutylpiperazinyl)- propyl] -2'-trifluoromethylsulfonylphenothiazine.
A mixture of 5.3 g. of the free base in 100 ml. of henzene and 3.6 g. of butyryl chloride is allowed to stand at room temperature for 12 hours. The reaction mixture is poured into water, neutralized and extracted with benzene. The residue upon-evaporation of solvent is the crude product, 10-[3'-(N-w-butyryloxybutylpiperazinyl)- propyl] -2-trifluoromethylsulfonylphenothiazine.
Example 25 A mixture of 10.8 g. of 10-(3'-hydroxypropyl)-2-trifiuoromethylsulfonylphenothiazine p toluenesulfonate (prepared as outlined in Example 18), 5.0 g. of N- hydroxyethoxyethylpiperazine and 4.2 g. of potassium carbonate in 150 ml. of ethanol is heated at reflux for six hours, with stirring. The reaction mixture is treated with water, evaporated in vacuo and extracted with ethyl acetate. Evaporation of the dried solvent yields the product, 10 [3' (N hydroxyethoxyethylpiperazinyl) propyl] 2-trifluoromethylsulfonylphenothiazine.
Example 26 A suspension of 33.1 g. of Z-trifiuoromethylsulfonylphenothiazine (prepared as in Example 1), 4.1 g. of sodamide and 29.3 g. of 3-chloro-1-(N-phenethylpiperazinyl) propane in 500 m1. of toluene is refluxed for eight hours. Working up as in Example 20, the dimaleate salt of 10- 3'- (N-phenethylpiperazinyl) -propyl] -2-trifluor0- methylsulfonylphenothiazine is obtained.
Example 27 To a stirred mixture of 9.1 g. of 10"(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine (made as in Example 6), dissolved in 500 ml. of benzeneand 10 ml. of pyridine is added 6.0 g. of acetic anhydride. The resulting mixture is allowed to stand for 16 hours, washed with water and evaporated to dryness. The residue is dissolved in alcohol and reacted with one equivalent of hydrochloric acid to give 10-[3-(N-acetylpiperazinyl)- propyl] 2 trifluoromethylsulfonylphenothiazine hydrochloride.
Example 28 A mixture of 9.1 g. of l-(3'-piperazinylpropyl)-2-trifluoromethylsulfonylphenothiazine (made as in Example 6) and 9.4 g. of benzoyl chloride in 300 ml. of benzene is refluxed for eight hours. Concentration of the reaction mixture yields -[3'-(N-benzoylpiperazinyl)-propyl]-2 trifiuoromethylsulfonylphenothiazine hydrochloride.
Example 29 SO50 F,
10 9 N r 2 .l z
in which Z is a member selected from the group consisting of amino, monoalkylamino, dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, N-alkylpiperazinyl, N-(w-hydroxyalkylene)-piperazinyl, N-(waikanoyloxyalkylene)- piperazinyl, N-(w-benzoyloxyalkylene)-piperazinyl, N-(wdialkylaminoalkylene)-piperazinyl, N-(w-hydroxy alkyleneoxy-alkylene)-piperazinyl, N-cinnamylpiperazinyl, N- phenethylpiperazinyl, N-alkanoylpiperazinyl, N-phenylalkanoylpiperazinyl, N-benzoylpiperazinyl, N-carbobenzoxypiperazinyl, N-dialkyl carbamylpiperazinyl, N, 2,3,5,6-
pentamethylpiperazinyl and N-methyl-Z,S-diethylpiperazinyl; and A is an alkylene chain having 2 to 6 carbon atoms and separating the nitrogens to which it is attached by at least 2 carbon atoms; each of the said alkyl moieties having 1 to 6 carbon atoms and each of the said alkylene and alkanoyl moieties having 2 to 6 carbon atoms.
2. A chemical compound having the basic structural formula:
S g @S 020 Fa CHz-GHr-G Hr-N 3. A chemical compound having the basic structural formula:
4. A chemical compound having the basic structural formula:
(IN/@8020 F; l
in which A is an alkylene chain having 2 to 6 carbon atoms andseparating the nitrogens to which it is attached by at least 2 carbon atoms; and R; is alkyl having to 1 to 6 carbon atoms.
5. A chemical compound having the basic structural formula:
SOICF3 N iilHr-CHrCHg-N N-CH;
6. A chemical compound having the basic structural formula:
HrCH-CHz-N N-CH3 7. A chemical compound having the basic structural formula:
in which A is an alkylene chain having 2 to 6 carbon atoms and separating the nitrogens to which it is attached by at least 2 carbon atoms; and R is w-hydroxyalkylene having 2 to 6 carbon atoms.
13 14 8. A chemical compound having the basic structural in which A is an alkylene chainhaving 2 to 6 carbon formula: atoms and separating the nitrogens to which it is attached 8 by at least 2 carbon atoms; and R is w-alkanoyloxyalkylene, the alkanoyl and alkylene moieties each having 2 to 5 6 carbon atoms.
N S02 10. A chemical compound having the basic structural formula:
Hz-OHg-CHr-N N-CHg-CHz-OH S 9. A chemical compound having the basic structural 10 formula: \N 8 0,0
CH 0 CH Hr-CHg-CHz-N N r- Hz-O l N SOQGF; 15
No references cited. l m
Claims (1)
1. A CHEMICAL COMPOUND OF THE CLASS CONSISTING OF A FREE BASE AND ITS NONTOXIC ACID ADDITION SALTS, THE FREE BASE HAVING THE FORMULA:
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE568478D BE568478A (en) | 1957-06-10 | ||
| US728773A US2914528A (en) | 1958-04-16 | 1958-04-16 | Substituted phenothiazinyl trifluoro-methyl sulfones |
| GB2640/60A GB851887A (en) | 1957-06-10 | 1958-06-03 | Substituted phenothiazinyl trifluoromethyl sulfones |
| GB17724/58A GB851886A (en) | 1957-06-10 | 1958-06-03 | Substituted phenothiazinyl trifluoromethyl sulfones |
| DES58547A DE1173099B (en) | 1957-06-10 | 1958-06-09 | Process for the preparation of trifluoromethylsulfonyl-phenthiazines with basic substitution in the 10-position |
| FR767619A FR1245551A (en) | 1957-06-10 | 1958-06-10 | Process for the preparation of substituted thiazinyl trifluoromethyl sulfones |
| US803090A US2919272A (en) | 1957-06-10 | 1959-03-31 | Substituted phenothiazinyl trifluoromethyl sulfones |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US728773A US2914528A (en) | 1958-04-16 | 1958-04-16 | Substituted phenothiazinyl trifluoro-methyl sulfones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2914528A true US2914528A (en) | 1959-11-24 |
Family
ID=24928225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US728773A Expired - Lifetime US2914528A (en) | 1957-06-10 | 1958-04-16 | Substituted phenothiazinyl trifluoro-methyl sulfones |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2914528A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3000886A (en) * | 1958-10-06 | 1961-09-19 | Smith Kline French Lab | Substituted aroylalkyl phenothiazinylalkyl piperazines |
| US3133917A (en) * | 1964-05-19 | Substituted trifluoromethoxy- and tri- | ||
| US3189657A (en) * | 1960-11-03 | 1965-06-15 | Lilly Co Eli | 5-(3-bromopropylidene) dibenzo-[a, d] cyclohepta (1.4)diene |
| US20040242570A1 (en) * | 2001-09-27 | 2004-12-02 | Abraham Nudelman | Conjugated psychotropic drugs and uses thereof |
| US20090298814A1 (en) * | 2005-06-07 | 2009-12-03 | Ramot At Tel Aviv Univeristy Ltd | Novel salts of conjugated psychotropic drugs and processes of preparing same |
| US20090304584A1 (en) * | 2006-07-17 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders |
| US20110034553A1 (en) * | 2008-02-11 | 2011-02-10 | Ramot At Tel-Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
| US20110178073A1 (en) * | 2009-12-09 | 2011-07-21 | Geffen Yona | Methods of improving cognitive functions |
| US8916610B2 (en) | 2010-09-22 | 2014-12-23 | Ramot At Tel-Aviv University Ltd. | Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same |
-
1958
- 1958-04-16 US US728773A patent/US2914528A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133917A (en) * | 1964-05-19 | Substituted trifluoromethoxy- and tri- | ||
| US3000886A (en) * | 1958-10-06 | 1961-09-19 | Smith Kline French Lab | Substituted aroylalkyl phenothiazinylalkyl piperazines |
| US3189657A (en) * | 1960-11-03 | 1965-06-15 | Lilly Co Eli | 5-(3-bromopropylidene) dibenzo-[a, d] cyclohepta (1.4)diene |
| US20100204469A1 (en) * | 2001-09-27 | 2010-08-12 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US7939525B2 (en) | 2001-09-27 | 2011-05-10 | Bar-Ilan University | Conjugated psychotropic drugs and uses thereof |
| US7598239B2 (en) * | 2001-09-27 | 2009-10-06 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US7619006B2 (en) * | 2001-09-27 | 2009-11-17 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US8283381B2 (en) | 2001-09-27 | 2012-10-09 | Ramot At Tel-Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US8168628B2 (en) | 2001-09-27 | 2012-05-01 | Ramot At Tel-Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US20100063034A1 (en) * | 2001-09-27 | 2010-03-11 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US20100120755A1 (en) * | 2001-09-27 | 2010-05-13 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US7544681B2 (en) * | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| US20040242570A1 (en) * | 2001-09-27 | 2004-12-02 | Abraham Nudelman | Conjugated psychotropic drugs and uses thereof |
| US20090298814A1 (en) * | 2005-06-07 | 2009-12-03 | Ramot At Tel Aviv Univeristy Ltd | Novel salts of conjugated psychotropic drugs and processes of preparing same |
| US20100144869A1 (en) * | 2006-07-17 | 2010-06-10 | Abraham Nudelman | Conjugates Comprising a gaba-or glycine compound, pharmaceutical compositions and combinations thereof as well as their use in treating cns disorders |
| US20090304584A1 (en) * | 2006-07-17 | 2009-12-10 | Ramot At Tel Aviv University Ltd. | Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders |
| US8222296B2 (en) | 2006-07-17 | 2012-07-17 | Ramot At Tel-Aviv University Ltd. | Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders |
| US8377990B2 (en) | 2006-07-17 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders |
| US20110034553A1 (en) * | 2008-02-11 | 2011-02-10 | Ramot At Tel-Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
| US8207369B2 (en) | 2008-02-11 | 2012-06-26 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
| US8722923B2 (en) | 2008-02-11 | 2014-05-13 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
| US20110178073A1 (en) * | 2009-12-09 | 2011-07-21 | Geffen Yona | Methods of improving cognitive functions |
| US8975251B2 (en) | 2009-12-09 | 2015-03-10 | Bar-Ilan University | Methods of improving cognitive functions |
| US8916610B2 (en) | 2010-09-22 | 2014-12-23 | Ramot At Tel-Aviv University Ltd. | Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2921069A (en) | Substituted trifluroromethylpheno-thiazine derivatives | |
| US3058979A (en) | New perfluoroalkylphenothiazine derivatives | |
| US2914528A (en) | Substituted phenothiazinyl trifluoro-methyl sulfones | |
| US3296252A (en) | Tetracyclic diazepinone compounds | |
| US3074931A (en) | Dibenzazepines | |
| US3192204A (en) | Trifluoromethylthiaxanthene and -xanthene derivatives | |
| US2877224A (en) | 3-cyano substituted phenothiazines | |
| HU191301B (en) | Process for preparing 1-/hydroxy-methyl/-1,6,7,11b-tetrahydro-2h,4h-/1,3/-oxazino- or -thiazino/4,3-a/isoquinoline -derivatives | |
| US4640916A (en) | 1,4-benzothiazine derivatives, compositions containing them and method of use | |
| US3532702A (en) | 2-(o-aminophenoxy or phenylthio) phenyl-1-substituted (piperidyl or pyrrolidinyl) ketones | |
| US2889322A (en) | 3-methanesulphonyl phenthiazine derivatives | |
| US2919272A (en) | Substituted phenothiazinyl trifluoromethyl sulfones | |
| DE1695132A1 (en) | Process for the preparation of heterocyclic compounds | |
| US2956996A (en) | Alkylated phenotfflazenecarboxamede | |
| US3647800A (en) | 10-substituted - 1 2 3 4 - tetrahydrobenzo(b)(1 6)naphthyridines useful as cns depressants | |
| US3068222A (en) | Trifluoromethyl substituted dibenzxze- | |
| CA1177830A (en) | Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents | |
| NL8002610A (en) | HETEROCYCLIC COMPOUNDS AND METHODS FOR PREPARING AND USING THESE COMPOUNDS. | |
| US3637706A (en) | 10-(4 - (lower)alkylpiperazino) - 1 2 3 4-tetrahydrobenzo(b)(1 6) naphthyridine derivatives useful as cns depressants | |
| US2944054A (en) | Substituted phenothiazinylalkyl aminosulfonylpiperazines | |
| US3470168A (en) | 2-substituted-4h-1,3-benzothiazin-4-one derivatives | |
| US3481921A (en) | Benzodiazepines | |
| US3574204A (en) | Piperidine spiro compounds | |
| US2979502A (en) | Phenthiazine derivatives | |
| US2944053A (en) | Uiiilcu |